ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Specific microRNAs may function to regulate BCR-ABL expression in CML patients and influence resistance to tyrosine kinase inhibitors, further affecting the prognosis or pathogenesis of CML patients [10].